| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 17/05/2024 | 13:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 17/05/2024 | 13:00 | Business Wire | Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 08/05/2024 | 13:07 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 08/05/2024 | 13:00 | Business Wire | Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 02/05/2024 | 14:00 | Business Wire | Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 01/05/2024 | 14:00 | Business Wire | Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024 | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 15/04/2024 | 13:00 | Business Wire | Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 05/04/2024 | 22:00 | Business Wire | Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 27/03/2024 | 13:41 | Business Wire | Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 05/03/2024 | 22:14 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 05/03/2024 | 22:01 | Business Wire | Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 22/02/2024 | 22:05 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 21/02/2024 | 13:00 | Business Wire | Marinus Pharmaceuticals to Present at Upcoming Investor Conferences | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 20/02/2024 | 13:00 | Business Wire | Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 14/02/2024 | 22:18 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 04/01/2024 | 13:01 | Business Wire | Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 20/11/2023 | 22:01 | Business Wire | Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 14/11/2023 | 22:05 | Business Wire | Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 07/11/2023 | 13:01 | Business Wire | Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 07/11/2023 | 13:00 | Business Wire | Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CV | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 24/10/2023 | 13:01 | Business Wire | Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023 | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 10/10/2023 | 22:01 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 21/09/2023 | 22:00 | Business Wire | Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 19/09/2023 | 14:00 | Business Wire | Marinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst Event | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 12/09/2023 | 22:00 | Business Wire | Marinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023 | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 17/08/2023 | 22:01 | Business Wire | Marinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023 | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 10/08/2023 | 13:01 | Business Wire | Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 31/07/2023 | 13:01 | Business Wire | Marinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 27/07/2023 | 13:01 | Business Wire | Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023 | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |
| 29/06/2023 | 12:01 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:MRNS | Marinus Pharmaceuticals Inc |